Peer Review History

Original SubmissionFebruary 24, 2026
Decision Letter - Hean Teik Ong, Editor

-->PONE-D-26-05846-->-->Exercise-based cardiac rehabilitation and atherosclerotic plaque regression in ASCVD: is exercise really a game-changer?  A scoping review of controlled trials-->-->PLOS One

Dear Dr.  Desandri,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.-->--> -->-->Please submit your revised manuscript by Apr 30 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:-->

  • A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

-->If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols..

We look forward to receiving your revised manuscript.

Kind regards,

Hean Teik Ong, FRCP, FACC

Academic Editor

PLOS One

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1.Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information..

3. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise.

4. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

Additional Editor Comments:

Please make minor revision to address the comments of the reviewers.

[Note: HTML markup is below. Please do not edit.]

Reviewer's Responses to Questions

-->Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. -->

Reviewer #1: Yes

Reviewer #2: Yes

**********

-->2. Has the statistical analysis been performed appropriately and rigorously? -->

Reviewer #1: Yes

Reviewer #2: Yes

**********

-->3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.-->

Reviewer #1: Yes

Reviewer #2: Yes

**********

-->4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.-->

Reviewer #1: Yes

Reviewer #2: Yes

**********

-->5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)-->

Reviewer #1: Full title: Is ( capital I) exercise really a game-changer?

Strong points of this paper:

1. Stringent criteria to select researches to answer the relevant question. Out of 425 researches only 5 were selected for analysis.

2. ⁠The mechanism of regression of atherosclerotic plaque from CR is discussed too —- reduction in inflammatory markers.

3. ⁠Synergetic effects of CR and LLTs is emphasised in this paper.

The main limitations of this paper are :

1. Unable to distinguish the role of lipid-lowering therapies in the regression of atherosclerotic plaque (As pointed out by the authors )

2. No hard endpoints and cardiovascular outcomes —- due to short duration follow up

3. ⁠Different CR Regimes, hence unable to identify the effective CR Intervention

4. ⁠The 5 studies analysed in this paper are either open label RCT (four) or non RCT (one)—- many confounding factors.

Nevertheless this paper studies a very important aspect of role of CR which is usually underutilised for secondary cardiovascular diseases prevention. I think it should be used as a hypothesis generating evidence for researchers to do more researches on this issue using RCT—- larger numbers, long term follow up and perhaps hard endpoints study (cardiovascular disease and death) on top of surrogate endpoints ( imaging studies )

Reviewer #2: his scoping review highlights the promising role of exercise-based cardiac rehabilitation (CR) in promoting atherosclerotic plaque regression. By utilizing modalities like HIIT and resistance training alongside standard medical therapy, CR demonstrated significant reductions in plaque volume and improved inflammatory markers across five trials.

However, the review’s conclusions are weakened by critical missing factor of selected studies: the lack of data on statin adherence. Since lipid-lowering therapies are the primary drivers of plaque regression, failing to control for medication compliance makes it difficult to isolate exercise as the definitive "game-changer." Consequently, while CR is an indispensable tool for secondary prevention, large-scale randomized controlled trials are essential to determine if exercise independently drives regression or merely supports pharmacological intervention.

**********

-->6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our For information about this choice, including consent withdrawal, please see our Privacy Policy..-->

Reviewer #1: No

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures

You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation.

NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications.

-->

Revision 1

Responses to Reviewer

Reviewer 1:

Full title: Is (capital I) exercise really a game-changer?

Strong points of this paper:

1. Stringent criteria to select researches to answer the relevant question. Out of 425 researches only 5 were selected for analysis.

2. ⁠The mechanism of regression of atherosclerotic plaque from CR is discussed too —reduction in inflammatory markers.

3. ⁠Synergetic effects of CR and LLTs is emphasised in this paper.

The main limitations of this paper are :

1. Unable to distinguish the role of lipid-lowering therapies in the regression of atherosclerotic plaque (As pointed out by the authors)

2. No hard endpoints and cardiovascular outcomes — due to short duration follow up

3. ⁠Different CR Regimes, hence unable to identify the effective CR Intervention

4. ⁠The 5 studies analysed in this paper are either open label RCT (four) or non RCT (one)—many confounding factors.

Nevertheless this paper studies a very important aspect of role of CR which is usually underutilised for secondary cardiovascular diseases prevention. I think it should be used as a hypothesis generating evidence for researchers to do more researches on this issue using RCT— larger numbers, long term follow up and perhaps hard endpoints study (cardiovascular disease and death) on top of surrogate endpoints (imaging studies)

Response:

The authors wish to express their sincere gratitude to the reviewer for their constructive insights and comprehensive evaluation of both the strengths and the primary limitations of this manuscript. We have carefully addressed each point raised to enhance the clarity and rigor of the work.

Response to Technical and Formatting Corrections:

The authors have corrected the typographical error in the title as identified. Specifically, the notation has been amended to the formal capitalized (I).

Response to Study Limitations:

Regarding the substantive limitations noted by the reviewer, the authors have conducted a thorough re-evaluation of the data and the existing literature. We fully acknowledge these constraints and have significantly expanded the Study Limitations section to provide a more critical and transparent discussion of the findings. These revisions can be found on pages 14–15, lines 231–240, “There are several limitations in this review. Firstly, the current analysis was unable to independently distinguish the specific role of concomitant LLTs in the observed regression of atherosclerotic plaque, a factor that remains a potential confounder in evaluating the primary intervention. Lack of information on drug adherence prevents us from determining whether plaque regression is directly attributable to CR. Second, the relatively short duration of follow-up across the included studies precluded the assessment of clinical endpoints and long-term cardiovascular outcomes. Third, significant heterogeneity in the CR regimens utilized across the literature makes it challenging to identify the most effective specific CR intervention. Lastly, although grey literature was considered, no relevant records were identified.”

Regarding the identified study limitations, the authors have further enhanced the manuscript’s academic contribution by incorporating a dedicated discussion on Future Research Directions. This newly added paragraph addresses the current gaps in the literature and outlines a strategic framework for subsequent investigations. These revisions are detailed on page 15, lines 241–250, “Based on the limitations identified in this study, future research should prioritize several key areas to bridge the current gaps in cardiovascular rehabilitation and plaque management, including (1) dissecting therapeutic synergy to accurately isolate the regression of atherosclerotic plaque. Future trials must be designed to distinguish the independent and effects of LLTs versus lifestyle-based CR intervention. (2) Long-term outcome data, there is a critical need for studies with extended follow-up duration in the aim to obtained hard clinical endpoints, including MACE, cardiovascular mortality, and all-cause hospitalization. (3) Future evidence synthesis would benefit from a higher volume of double-blind and multicenter RCTs, providing a clearer picture of the intervention’s true efficacy. (4) Leveraging high-resolution intravascular imaging in future cohorts could provide deeper insights into plaque morphology and stability beyond simple volume regression.”

Reviewer 2:

This scoping review highlights the promising role of exercise-based cardiac rehabilitation (CR) in promoting atherosclerotic plaque regression. By utilizing modalities like HIIT and resistance training alongside standard medical therapy, CR demonstrated significant reductions in plaque volume and improved inflammatory markers across five trials.

However, the review’s conclusions are weakened by critical missing factor of selected studies: the lack of data on statin adherence. Since lipid-lowering therapies are the primary drivers of plaque regression, failing to control for medication compliance makes it difficult to isolate exercise as the definitive "game-changer." Consequently, while CR is an indispensable tool for secondary prevention, large-scale randomized controlled trials are essential to determine if exercise independently drives regression or merely supports pharmacological intervention.

Response:

The authors wish to express their sincere appreciation for the reviewer’s constructive and insightful comments regarding these critical points. Related to the issues that mentioned above, the authors have been studied and investigate thoroughly. Therefore, in facing the issues the authors have been modified the limitation contents on pages 14–15, lines 233 – 235 related to the lack of data on statin adherence. Furthermore, to preserve the thematic context of the 'game-changer' hypothesis while responding to the reviewer’s concerns, we have incorporated a dedicated Future Research Directions section (page 15, lines 241–250). This addition serves to outline a strategic framework for subsequent investigations to systematically accommodate and mitigate the issues constraints identified in the present study.

Attachments
Attachment
Submitted filename: Response to Reviewers.docx
Decision Letter - Hean Teik Ong, Editor

Exercise-based cardiac rehabilitation and atherosclerotic plaque regression in ASCVD: Is exercise really a game-changer?  A scoping review of controlled trials

PONE-D-26-05846R1

Dear Dr. Dwita Rian Desandri,

Congratulations, your article has been accepted by the academic editor and reviewers.  You now have to meet requirements from the administrative editors, if any.

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact  and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact billing support..

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Hean Teik Ong, FRCP, FACC

Academic Editor

PLOS One

Additional Editor Comments (optional):

Congratulations, your article has been accepted by the academic editor and reviewers. You now have to meet requirements from the administrative editors, if any.

Reviewers' comments:

Reviewer's Responses to Questions

-->Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.-->

Reviewer #1: All comments have been addressed

Reviewer #2: (No Response)

**********

-->2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. -->

Reviewer #1: Yes

Reviewer #2: (No Response)

**********

-->3. Has the statistical analysis been performed appropriately and rigorously? -->

Reviewer #1: Yes

Reviewer #2: (No Response)

**********

-->4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.-->

Reviewer #1: Yes

Reviewer #2: (No Response)

**********

-->5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.-->

Reviewer #1: Yes

Reviewer #2: (No Response)

**********

-->6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)-->

Reviewer #1: No further comment All my concerns are addressed.

The paper raised a good point to remind the clinicians the importance of incorporating exercise in the process of helping patients to prevent ASCVD.

Please publish accordingly

Reviewer #2: (No Response)

**********

-->7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our For information about this choice, including consent withdrawal, please see our Privacy Policy..-->

Reviewer #1: No

Reviewer #2: No

**********

Formally Accepted
Acceptance Letter - Hean Teik Ong, Editor

PONE-D-26-05846R1

PLOS One

Dear Dr. Desandri,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS One. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Hean Teik Ong

Academic Editor

PLOS One

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .